Development and evaluation of a national reference panel of HIV-1 protease and reverse transcriptase drug-resistance mutations for HIV-1 genotypic resistance assays in China

Molecular Diagnosis and Therapy

Volumn 14, Issue 1, 2010, Pages 31-41

  Xu, Sihong ^a   Li, Jingyun ^b   Bao, Zuoyi ^b   Xing, Hui ^c   Zhong, Ping ^d   Li, Hanping ^b   Zhou, Haiwei ^c   Li, Xinping ^e   Wu, Sharon ^e   Song, Aijing ^a   Li, Xiuhua ^a   Nie, Jianhui ^a   Wang, Youchun ^a  

^a NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d Shanghai Center for Disease Control and Prevention   (China)

^e Abbott China   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CHINA; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS CULTURE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 76949095330     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/BF03256351     Document Type: Article

References (29)

1. Sayer DC, Land S, Gizzarelli L, et al. Quality assessment program for genotypic antiretroviral testing improves detection of drug resistance mutations. J Clin Microbiol 2003; 41: 227-236
2. Brenner B,Wainberg MA, Salomon H, et al. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. Int J Antimicrob Agents 2000; 16: 429-434
3. Chaix ML, Descamps D, Harzic M, et al. Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS 2003; 17: 2635-2643
4. Descamps D, Chaix ML, Andre P, et al. French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr 2005; 38: 545-552
5. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-394
6. Masquelier B, Bhaskaran K, Pillay D, et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr 2005; 40: 505-511
7. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drugresistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192: 958-966
8. Yerly S, Von Wyl V, Ledergerber B, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-yearmolecular epidemiology survey.AIDS 2007; 21: 2223-2229
9. Yerly S, Kaiser L, Race E, et al. Transmission of antiretroviral-drug- resistant HIV-1 variants. Lancet 1999; 354: 729-733
10. HirschMS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37: 113-128
11. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2008; 47: 266-285
12. Garcia-Perez J, Sanchez-Palomino S, Perez-Olmeda M, et al. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1. J Med Virol 2007; 79: 127-137
13. Zhang H, Zhou Y, Alcock C, et al. Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol 2004; 78: 1718-1729
14. Baxter JD, Mayers DL,Wentworth DN, et al., and the CPCRA Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy [abstract. no. LB 8]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago (IL)
15. Durant J, Clevenbergh P, Halfon P, et al. Improving HIV therapy with drug resistance genotyping: the VIRADAPT randomised study. Lancet 1999; 353: 2195-2199
16. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science 1998; 280: 1871-1873
17. Schuurman R, Demeter L, Reichelderfer P, et al. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 1999; 37: 2291-2296
18. DeGruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5: 41-48
19. Shafer RW, Jung DR, Betts BJ. Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. NatMed 2000; 6: 1290-1292
20. Rousseau MN, Vergne L, Montes B, et al. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. JAcquir ImmuneDefic Syndr 2001; 26: 36-43
21. Erice A, Sannerud KJ, Leske VL, et al. Sensitive microculture method for isolation of human immunodeficiency virus type 1 from blood leukocytes. J Clin Microbiol 1992; 30: 444-448
22. Shafer RW, Warford A, Winters MA, et al. Reproducibility of human immunodeficiency virus type 1 (HIV-1) protease and reverse transcriptase sequencing of plasma samples from heavily treated HIV-1-infected individuals. J Virol Methods 2000; 86: 143-153
23. Zhong P, Pan Q, Ning Z, et al. Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. AIDS Res Hum Retroviruses 2007; 23 (7): 847-856
24. Maes B, Schrooten Y, Snoeck J, et al. Performance of ViroSeq HIV-1 genotyping system in routine practice at a Belgian clinical laboratory. J Virol Methods 2004; 119: 45-49
25. Descamps D, Delaugerre C, Masquelier B, et al. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol 2006; 78: 153-160
26. Ross L, BoulmeR, FisherR, et al.Adirect comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms. AIDS Res Hum Retroviruses 2005a; 21: 933-939
27. Ross L, Boulme R, Fusco G, et al. Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort. AIDS Res Hum Retroviruses 2005; 21: 696-701
28. Korn K, Reil H, Walter H, et al. Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results. J Clin Microbiol 2003; 41: 3559-3565
29. Huang DD, Eshleman SH, Brambilla DJ, et al. Evaluation of the editing process in human immunodeficiency virus type 1 genotyping. JClin Microbiol 2003; 41: 3265-3272